Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy

被引:48
|
作者
Grzeskowiak, Luke E. [1 ]
Gilbert, Andrew L. [1 ]
Morrison, Janna L. [2 ]
机构
[1] Univ S Australia, Sansom Inst Hlth Res, Sch Pharm & Med Sci, Qual Use Med & Pharm Res Ctr, Adelaide, SA 5001, Australia
[2] Univ S Australia, Sansom Inst Hlth Res, Sch Pharm & Med Sci, Early Origins Adult Hlth Res Grp, Adelaide, SA 5001, Australia
关键词
Pharmacy records; Drug exposure; Pregnancy; Pharmacoepidemiology; Methodology; SEROTONIN REUPTAKE INHIBITORS; POPULATION-BASED COHORT; CONGENITAL-MALFORMATIONS; PRENATAL EXPOSURE; HEALTH DATA; INFANTS; WOMEN; ANTIDEPRESSANTS; 1ST-TRIMESTER; DEPRESSION;
D O I
10.1007/s00228-011-1154-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this systematic review was to examine and compare differences in the way medication exposures are classified in studies using linked administrative data to investigate outcomes following medication use during pregnancy. This was undertaken with a focus on studies investigating specific neonatal outcomes following prenatal exposure to selective serotonin reuptake inhibitors (SSRIs). We searched Medline and Embase to identify studies that used linked administrative data to investigate specific neonatal outcomes (congenital malformations, birth weight, gestational age) following prenatal exposure to SSRIs. Key factors such as dose, duration and timing of exposure were inconsistently addressed in the studies identified. In addition, there was a great deal of variability in the way medication exposures were classified and how women who stop taking their medication before or during early pregnancy are handled in analyses. Furthermore, there are issues in assuming how and when women who receive a dispensing for a medication actually take it during pregnancy. This creates a great deal of uncertainty around medication exposure during pregnancy in studies using linked administrative data, potentially resulting in biased risk estimates. There is a need for greater focus on determining the most effective and accurate way of using linked administrative data to investigate outcomes following medication use during pregnancy in an effort to minimise potential biases.
引用
收藏
页码:459 / 467
页数:9
相关论文
共 27 条
  • [1] Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy
    Luke E. Grzeskowiak
    Andrew L. Gilbert
    Janna L. Morrison
    European Journal of Clinical Pharmacology, 2012, 68 : 459 - 467
  • [2] Use of administrative claims data in observational studies of antirheumatic medication effects on pregnancy outcomes: a scoping review protocol
    Tharmarajah, Shenthuraan
    Guilcher, Sara
    Santhireswaran, Araniy
    Mccarthy, Lisa
    Mahendira, Dharini
    Berger, Howard
    Tadrous, Mina
    JBI EVIDENCE SYNTHESIS, 2024, 22 (01) : 106 - 115
  • [3] The use of parent-completed questionnaires to investigate developmental outcomes in large populations of children exposed to antiseizure medications in pregnancy
    Bluett-Duncan, Matthew
    Bullen, Philip
    Campbell, Ellen
    Clayton-Smith, Jill
    Craig, John
    Garcia-Finana, Marta
    Hughes, David M.
    Ingham, Amy
    Irwin, Beth
    Jackson, Cerian
    Kelly, Teresa
    Morrow, James
    Rushton, Sarah
    Winterbottom, Janine
    Wood, Amanda G.
    Yates, Laura M.
    Bromley, Rebecca L.
    EPILEPSIA, 2024, 65 (07) : 2017 - 2029
  • [4] Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data
    Swanson, Sonja A.
    Hernandez-Diaz, Sonia
    Palmsten, Kristin
    Mogun, Helen
    Olfson, Mark
    Huybrechts, Krista F.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 (09) : 934 - 942
  • [5] Methodological challenges in using routinely collected health data to investigate long-term effects of medication use during pregnancy
    Grzeskowiak, Luke E.
    Gilbert, Andrew L.
    Morrison, Janna L.
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2013, 4 (01) : 27 - 37
  • [6] Using Routinely Collected Health Data to Investigate Long-Term Effects of Medication Use during Pregnancy: Challenges and Opportunities
    Grzeskowiak, L. E.
    Gilbert, A. L.
    Morrison, J. L.
    BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2012, 94 (05) : 346 - 346
  • [7] Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design
    Williams, Paige L.
    Hazra, Rohan
    Van Dyke, Russell B.
    Yildirim, Cenk
    Crain, Marilyn J.
    Seage, George R., III
    Civitello, Lucy
    Ellis, Angela
    Butler, Laurie
    Rich, Kenneth
    AIDS, 2016, 30 (01) : 133 - 144
  • [8] Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants
    Siberry, George K.
    Williams, Paige L.
    Mendez, Hermann
    Seage, George R., III
    Jacobson, Denise L.
    Hazra, Rohan
    Rich, Kenneth C.
    Griner, Raymond
    Tassiopoulos, Katherine
    Kacanek, Deborah
    Mofenson, Lynne M.
    Miller, Tracie
    DiMeglio, Linda A.
    Watts, D. Heather
    AIDS, 2012, 26 (09) : 1151 - 1159
  • [9] Combining adverse pregnancy and perinatal outcomes for women exposed to antiepileptic drugs during pregnancy, using a latent trait model
    Xuerong Wen
    Abraham Hartzema
    Joseph A. Delaney
    Babette Brumback
    Xuefeng Liu
    Robert Egerman
    Jeffrey Roth
    Rich Segal
    Kimford J. Meador
    BMC Pregnancy and Childbirth, 17
  • [10] Combining adverse pregnancy and perinatal outcomes for women exposed to antiepileptic drugs during pregnancy, using a latent trait model
    Wen, Xuerong
    Hartzema, Abraham
    Delaney, Joseph A.
    Brumback, Babette
    Liu, Xuefeng
    Egerman, Robert
    Roth, Jeffrey
    Segal, Rich
    Meador, Kimford J.
    BMC PREGNANCY AND CHILDBIRTH, 2017, 17